In order to establish the therapeutic plasma concentration of famotidine, the 24-h intragastric pH response to low-dose intravenous (i.v.) continuous infusion of 40 (group A) or 20 mg/day (group B), administered over more than two days, was studied in 10 adult patients with active gastric ulcers (GU). In group A, the mean age was 64.8 years and in group B, 54.2 years. On the second day, 4 blood samples were collected for famotidine assay and 24 h intragastric pH monitoring was performed. Results: the mean 24 h pH did not differ significantly (P < 0.01) bet ween group A at 6.9 and groupB at 7.2. Ingroup A, the percentage of time with pH above 6.0 and above 7.0 were 94.8 and 59.0, respectively, and the mean famotidine dose and plasma con centration were 0.81 mg/kg/day and 140.89ng/ml. In group B, the percentage of time with pH above 6.0 and 7.0 were 97.6 and 65.4, and the mean dose and famotidine concentration were 0.34mg/kg/day and 45.42 ng/ml. In conclusion, in fasting patients with active gastric body ulcers, continuous infusions of low-dose famotidine maintain both the therapeutic plasmatic concentration and the intragastric pH to near anacidity level. (Internal Medicine 31: 299-303, 1992) 
Introduction

Materials and Methods
Proximally located gastric ulcers (GU) tend to occur in the elderly (1). Due to the increased risk of complications, many of these patients with active GU are thought to require hospitalization. Intragastric anacidity is desirable soon after admission to arrest or prevent hemorrhage (2, 3). However, most dosage studies have been performed in young subjects (either volunteers or asymptomatic patients). Also previous administration of H2-blockers impairs the pH response (4). All the above-mentioned reasons could explain why most 24h intragastric pH controlled reports up to the present recommend high doses of antisecretory intravenous (i.v.) infusions (5) (6) (7) (8) (9) (10) .
There is a wide variability in the i.v. dosage of H2-blockers presently used (6) (7) (8) (9) (10) and little attention has been paid to the effect of low doses. To establish a therapeutic plasma concentration and a dosage guideline, here the effect of 20 or 40mg/day famotidine on 24-h intragastric pH in active gastric body ulcer patients was analyzed.
Ten adult patients, 9 males and 1 female (8 were smokers) with ages ranging from 29 to 73 years (average 60 years), and body weight (b.w.) from 34-78kg (aver age 57kg) who were admitted for at least one of the following conditions were selected: melena, hema tochezia, anemia, hematemesis, or severe epigastric pain. The patients were fasting and they received daily either 40mg (group A) or 20mg (group B) of famotidine as a continuous infusion for more than two days. All of the eligible patients had at least one active GU (size determined by means of the Olympus measuring device) all of which were located at the gastric body and were confirmed to be benign by biopsy. Patients having ulcers with an exposed vessel as well as concomitant prepyloric or duodenal ulcers were not included. None of the patients had taken H2-blockers during the im mediate one week before commencing the study. Twenty-four-hour intragastric pH was monitored (recorded every 10 second from 9:00 AM to the following 9:00 AM) during the second day of continuous infusion by using a solid state pH memory (model CR-5501, Chemical Ins. Co. , Ltd, Tokyo) and combined electrodes (glass and reference electrode model CM-151 and CM 535, Chemical Ins. Co.). To deliver an uniform and steady infusion, a pump (model Ivac R 530, Ivac Co., San Diego, CA, USA) was used during the experiment; to assure compliance, the quantity of infusion was as sessed at the end of the first and second study days. The endoscopes used were Olympus model GIF K-10 and GF-10. For the famotidine assay, employing a modified method of Inotsume et al (ll) , the high performance liquid chromatography detector used was a Waters Lambda-Max model 481. After the clinical condition of the patients was stabil ized and when repeat endoscopic examination assured a low risk of rebleeding, the eligible patients underwent the study within the first week of hospitalization. Written consent was obtained according to the Helsinki declar ation. White blood count (WBC), renal, and hepatic clinical and laboratory tests, were performed upon ad mission, and during the time of and after the experiment. Oral administration of antacids or any other drug, as well as food and beverages were not allowed from 12h before the commencement of the pH monitoring. Elec trode calibration was performed with 4.0 and 7.0 standard pH solutions before and after each pH study. No elec trode drifting was observed. The glass electrode was advanced through a nostril and by means of fluoroscopic guidance manipulated until the distal end reached a free mobile position in a dependent portion of the gastric body according to methods of previous reports (12, 13). The distance from the measuring tip of the electrode to the cardia was 8-12cm . Throughout the pH recordings, patients remained in a recumbent position most of the time, but no special restrictions were made concerning ambulation. For the famotidine assay, 4 blood samples were collected. Plasma was obtained by immediate centrifugation of the blood samples and then stored at -20°C until analysis. Fluoroscopic reconfirmation of the electrode location was performed before withdrawal at the end of each study. After finishing each pH recording, data was trans ferred to floppy disks. Corrections were performed whenever an upward shift of the pH tracing was observed (13). Analysis was performed (personal computer NEC PC-9801) when all studies were complete. Individual data concerning the plasma concentration of famotidine (4 groups: 9:00, 15:00, 21:00 and the following day 9:00) as well as the percentage and time period with pH above 6.0 and 7.0 were considered to be the variables of the most interest for statistical comparisons (performed by the Wilcoxon signed rank test). Probability values of P < 0.05 were considered significant. Results Table 1 presents the demographic and clinical charac teristics of the ten patients. The group A was well matched (P<0.01) with group B regarding body weight, body surface, serum creatinine, ulcer number and size. More over, previous alcohol consumption level and the number of cigarettes per day were also similar in both groups. However, on average, the patients in group B were 10.6 years younger (group A: 64.8± SD 4.7; group B: 54.2 ± SD 16.5) and 5.5kg heavier (group A: 54.2kg ± DS 17.5, group B: 59.7kg± SD 6.3) than those in group A. Table 1 also shows that, in both groups, older patients with high or borderline serum creatinine had normal renal function (ll). By clinical, laboratory or endoscopic evidence, the gastric lesions were suspected as the site of the blood loss. In each patient, the diameter of the largest ulcer was 10-35mm (mean 17.5mm). Four patients had recurrent ulcers (two in each group), and three patients in group A and four in group B had 2 or more GU. Figure 1 depicts the individual and group mean pH tracings. Age did not affect the gastric pH response to Time (hours) Time (hours) famotidine in either group. As presented in Table 2 , in both groups, there was an almost 24-hour intragastric anacidity (pH S 7.0) with a mean overall pH value of 6.9 in group A and 7.2 in group B. In group A the percentage of time period with pH above 6.0 and 7.0 were 94.8 (22h 45 min) and 59.0 (14h lOmin) respectively. For group B, the corresponding results were 97.6 (23h 25min) and 65.4 (15 h 42 min). These differences were not statistically significant. Figure 2 illustrates the intergroup differences in plasma concentration of famotidine which were signifi cant (P<0-05) at all 4 times of examination. The mean concentration values, represented in Table 2 , showed more than a three-fold difference between the two groups which is not fully explanable by dose (in group A 0.81±SD 0.27mg/kgb.w. and in group B 0.34±SD 0.04mg/kgb.w., just slightly less than half of group A)
or renal function tests (ll). Also, there was an age- related, but not dose-related increase in famotidine con centration among patients in group B. The most likely explanation is that the difference in age (Table 1) was the primary contributing factor in the wide inter-individual (and indeed inter-group) plasma concentration range. As Table 2 shows, individual plasma concentrations were from 100.7 to 215ng/ml (mean 140.9±SD 30.1) in group A and from 8.1 to 130.1ng/ml (mean 45.4±SD 29.3) in group B. The data of the two groups overlapped at around 100ng/ml. In both groups, the greatest uni formity in famotidine concentration (the lowest SD) was achieved at 21:00, and the greatest variability was observed at the 9:00, the first sample. One subject in each group presented high variability in plasma con centration values. Tests of WBC, sodium, potassium, total bilirubin, glutamic and pyruvic y-glutamyl transferases, alkaline phosphatase and lactate dehydrogenase were normal at all examination times.
Discussion
The method of continuous infusions appears to be more useful for maintaining a high intragastric pH than intermittent infusion of identical doses (14) . A famotidine concentration of about 13 ng/ml has been considered to be the IC50. (15) Because in the elderly the half-life of famotidine is prolonged (ll), the mean famotidine concentrations in the 40mg/day group were as high as those generated by much higher doses administered to younger subjects,this could in itself explain the constant gastric pH response (7) . In order to test the effect of much lower steady-state plasma concentrations on gastric acidity, slightly younger subjects were purposely included in group B. We were surprised that even the 29-year-old patient with the lowest mean concentration (17.05 ± SD 9.41), presented a mean pH of 7.25, rather similar to that of the other patients (Table 2) . Considering the resultant differences in metabolic rates among patients, it could be expected that a con tinuous infusion of a dosage of between 0.3 and 0.4mg/ kg/day (mean 0.34mg/kg/day) at the second day gen erates steady concentrations of famotidine (Fig. 2) . In fasting patients with proximally located GU, these concentrations were high enough to maintain a 24-h intragastric pH near the 7.0 anacidity level (Fig. 1) . These results indicate that when continuous infusions are administered after admission there is not any ad ditional advantage in 24h intragastric pH derived from generating high plasma concentrations in patients with gastric body ulcers. Furthermore, the currently reported infusion doses of famotidine might actually be too high for the elderly. The amount of drug that patients with gastric body ulcer receive could be reduced and the cost effectiveness improved. Also, to prevent unnecessitated accumulation of famotidine in plasma the above proposed dosage regimen provides a good therapeutic alternative. Possible disturbances such as dislocation of the elec trode into the duodenum or esophagus, and hypo chlorydria, which might have resulted in spurious acid suppression in both groups, were ruled out firstly by the fluoroscopic control (12, 13), and secondly by the nadirs and the shape of the pH profiles.
In conclusion, the continuous infusion of low-dose famotidine (20 or 40mg/day) administered to fasting patients with active gastric body ulcers generates plasma concentrations within the therapeutic range. At both dosage levels the intragastric pH values were well above those traditionally considered significant (3) in the treat ment of upper gastrointestinal hemorrhage. Considering cost-utility and the possibility of dose-related mental confusion in the elderly (16) , the lower famotidine dosage (arm B of this study) is recommended.
